Monitor the appointment of the new CFO (Marie Washburn) and any related compensation terms. The proximity to the contested annual meeting (July 1, 2026) with proposals for massive share authorization and reverse split adds governance risk, watch for further insider moves or operational updates.
LGVN drugs
LGVN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 8 $0.7540entry
- T+1 · 5mo ago +2.48%α +2.77% · $0.7727
- T+5 · 5mo ago +4.77%α +2.66% · $0.7900
- T+20 · 4mo ago −14.72%α −15.56% · $0.6430
- T+60 · 3mo ago −10.08%α −13.59% · $0.6780
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CFO Lisa Locklear is stepping down effective July 10, 2026, with controller Marie Washburn expected to be elevated into the role. The departure is described as voluntary and not due to any disagreement with the company. This CFO change comes shortly after a contested proxy solicitation (DEFA14A filed May 20, 2026) that included proposals to increase authorized shares and effect a reverse stock split, adding governance uncertainty.
Key Facts
- CFO Lisa Locklear informed management on June 1, 2026 of her decision to step down, effective July 10, 2026.
- Controller Marie Washburn is anticipated to be elevated into the CFO role upon Locklear's departure, pending final contract.
- Locklear's resignation was not the result of any disagreement with the company regarding its operations, policies, or practices.
- A DEFA14A filed 16 days prior (May 20, 2026) proposes increasing authorized Class A common stock to 175,000,000 shares and a reverse stock split of 1:2 to 1:20.
Financial Impact
No financial figures reported in the filing.
Risk Factors
- CFO transition during a period of governance uncertainty (proxy contest, proposed reverse split, massive share authorization).
- Potential for further C-suite departures if the proxy proposals pass and the board composition changes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-065788 |
| Document: 0001213900-26-065788-index-headers.html | 0001213900-26-065788 |
| Document: 0001213900-26-065788-index.html | 0001213900-26-065788 |
| Document: 0001213900-26-065788.txt | 0001213900-26-065788 |
Track record
22 reports on LGVN
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +44.65% at T+20 after the Sep 16, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.53 Now $2.14 +15.42% settles Feb 12
- Nov 13, 20263d ago SC 13G Neutral 4/10 Entry $2.49 Now $2.14 −14.06% settles Feb 11
- Nov 12, 20264d ago 8-K Bearish 7/10 No price data
- Nov 12, 20264d ago Press Release Bearish 6/10 Entry $2.49 Now $2.14 +14.06% settles Feb 11
- Nov 5, 202611d ago SC 13G/A Bearish 5/10 Entry $1.81 Now $2.14 −18.23% settles Feb 4
- Nov 5, 202611d ago 8-K Neutral 2/10 Entry $1.81 Now $2.14 +18.23% settles Feb 4
- Oct 26, 202621d ago 8-K Neutral 5/10 Entry $1.73 Now $2.14 +23.70% settles Jan 25
- Oct 26, 202621d ago Press Release Mixed 6/10 Entry $1.61 Now $2.14 +33.33% settles Jan 22
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $1.50 Now $2.14 +42.67% settles Jan 12
- Sep 16, 20268w ago Press Release Bearish 7/10 Entry $2.71 Now $2.14 +21.03% settles Dec 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers